tiprankstipranks
Trending News
More News >
Grifols SA (GRFS)
:GRFS

Grifols SA (GRFS) AI Stock Analysis

Compare
439 Followers

Top Page

GR

Grifols SA

(NASDAQ:GRFS)

Rating:65Neutral
Price Target:
$9.50
▲(5.56%Upside)
Grifols SA's overall score reflects strong financial performance improvements and robust earnings, tempered by high leverage and valuation concerns. Technical indicators show bullish momentum but caution due to overbought signals. The earnings call confirmed positive growth trends, despite cash flow challenges.

Grifols SA (GRFS) vs. SPDR S&P 500 ETF (SPY)

Grifols SA Business Overview & Revenue Model

Company DescriptionGrifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
How the Company Makes MoneyGrifols SA primarily generates revenue through the sale of plasma-derived therapies, which are produced by its Bioscience division. This division is the largest contributor to the company's revenue, driven by the demand for its products in treating conditions such as hemophilia, primary immunodeficiencies, and alpha-1 antitrypsin deficiency. The Diagnostic division provides revenue through the sale of equipment and reagents used in blood testing and transfusion medicine. The Hospital division offers products for hospital pharmacy services, including solutions for intravenous therapy and clinical nutrition. Additionally, Grifols earns money through its Bio Supplies division, which supplies biological products for non-therapeutic use. Strategic partnerships with healthcare providers and research institutions, as well as investments in R&D, also play a vital role in sustaining and growing the company's revenue.

Grifols SA Earnings Call Summary

Earnings Call Date:May 12, 2025
(Q1-2025)
|
% Change Since: 26.76%|
Next Earnings Date:Jul 29, 2025
Earnings Call Sentiment Positive
Grifols reported strong Q1 2025 performance with record revenue and growth, particularly in the immunoglobulin franchise. Despite challenges like negative free cash flow due to a strategic payment and temporary albumin issues, the company showed robust adjusted EBITDA and continued deleveraging efforts. The results are ahead of plan even amidst macroeconomic uncertainties and IRA impacts.
Q1-2025 Updates
Positive Updates
Record Revenue and Growth in Q1 2025
Revenue in Q1 2025 reached EUR1.786 billion, a 7.4% increase on a constant currency basis. On a like-for-like basis, revenue increased by 10%.
Strong Adjusted EBITDA Performance
Adjusted EBITDA reached EUR400 million, an improvement of 14.2% at constant currency. Like-for-like, it grew by close to 22%.
Impressive Growth in Immunoglobulin Franchise
The immunoglobulin franchise achieved 17.5% growth in revenue at constant currency and like-for-like, with subcutaneous IG growing an impressive 91% at constant currency.
Improvement in Free Cash Flow
Free cash flow for the quarter was negative EUR44 million, but there was a year-on-year improvement of more than EUR200 million.
Continued Deleveraging
Leverage improved slightly from 4.6 times to under 4.5 times, marking a priority for the company.
Negative Updates
Negative Free Cash Flow Due to Strategic Payment
Free cash flow was negative EUR44 million, primarily due to a EUR79 million payment to ImmunoTek.
Temporary Albumin and Rabies Phasing Challenges
The phasing in albumins and rabies put some pressure on gross margin and EBITDA in Q1 '25.
Impact of IRA on Financial Performance
The difference between like-for-like and reported figures amounted to EUR43 million, with EUR28 million attributable to the IRA.
Albumin Sales Temporarily Affected
Albumin sales growth was temporarily affected by a standard license renewal process in China, resulting in a decline of 8.9% on a like-for-like basis.
Company Guidance
During the Q1 2025 earnings call, Grifols executives highlighted a robust start to the fiscal year, reporting revenue of EUR 1.786 billion—a 7.4% increase on a constant currency basis, which rises to 10% on a like-for-like basis. Adjusted EBITDA reached EUR 400 million, marking a 14.2% increase at constant currency and nearly 22% like-for-like. Despite a negative free cash flow of EUR 44 million, attributed to a EUR 79 million payment to ImmunoTek, the company achieved a year-on-year improvement in free cash flow by over EUR 200 million. The revenue growth was primarily driven by the biopharma segment, with the immunoglobulin franchise experiencing a 17.5% revenue increase on a constant currency basis. Management reaffirmed their 2025 guidance, anticipating continued revenue growth, enhanced profitability, and free cash flow improvements, underpinned by strategic initiatives and market dynamics.

Grifols SA Financial Statement Overview

Summary
Grifols SA shows strong revenue growth and improved operating margins. However, a low net profit margin and high leverage pose risks. Despite strong cash flow generation, further enhancement is needed for financial stability.
Income Statement
72
Positive
Grifols SA demonstrates strong revenue growth with a 9.41% increase from 2023 to 2024. The gross profit margin improved to 38.74%, indicating efficient cost management. However, the net profit margin remains relatively low at 2.18%, suggesting potential cost or operational inefficiencies. The EBIT margin increased to 16.53%, reflecting better operating performance.
Balance Sheet
65
Positive
The debt-to-equity ratio of 1.71 indicates a high level of leverage, which could pose risks if not managed properly. Return on equity is modest at 2.67%, suggesting room for improvement in profitability. The equity ratio of 27.49% highlights a stable asset base supported by equity, though there is reliance on debt.
Cash Flow
68
Positive
Grifols SA shows a significant improvement in free cash flow, turning positive in 2024. The operating cash flow to net income ratio of 5.75 reflects strong cash generation capacity relative to net profits. However, the free cash flow to net income ratio of 3.38 indicates that cash flow improvements are still needed to enhance financial flexibility.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue7.21B6.59B6.06B4.93B5.34B
Gross Profit2.79B2.32B2.23B1.96B2.26B
EBITDA1.48B1.18B1.16B922.47M1.37B
Net Income156.92M59.31M208.28M265.33M618.55M
Balance Sheet
Total Assets21.41B21.44B21.53B19.23B15.27B
Cash, Cash Equivalents and Short-Term Investments1.00B544.50M591.24M2.68B590.51M
Total Debt10.09B10.12B9.75B9.32B6.91B
Total Liabilities12.80B13.47B13.08B11.09B8.55B
Stockholders Equity5.88B5.83B6.13B6.10B5.11B
Cash Flow
Free Cash Flow530.80M-87.14M-386.43M281.89M747.78M
Operating Cash Flow902.17M208.28M-10.87M596.98M1.11B
Investing Cash Flow886.67M-397.64M-1.98B-29.39M-858.12M
Financing Cash Flow-1.36B186.04M-173.49M1.47B-354.40M

Grifols SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price9.00
Price Trends
50DMA
8.12
Positive
100DMA
7.81
Positive
200DMA
7.98
Positive
Market Momentum
MACD
0.22
Positive
RSI
64.57
Neutral
STOCH
93.92
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRFS, the sentiment is Positive. The current price of 9 is above the 20-day moving average (MA) of 8.82, above the 50-day MA of 8.12, and above the 200-day MA of 7.98, indicating a bullish trend. The MACD of 0.22 indicates Positive momentum. The RSI at 64.57 is Neutral, neither overbought nor oversold. The STOCH value of 93.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRFS.

Grifols SA Risk Analysis

Grifols SA disclosed 53 risk factors in its most recent earnings report. Grifols SA reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Grifols SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
PFPFE
72
Outperform
$142.36B18.158.62%6.87%13.38%
71
Outperform
$138.98B23.4932.51%2.83%4.63%1144.01%
SNSNY
67
Neutral
$119.58B20.417.34%4.51%-4.57%2.96%
GSGSK
66
Neutral
$78.51B19.9822.26%4.41%4.17%-29.96%
65
Neutral
$7.51B29.713.34%9.67%1.92%
BMBMY
63
Neutral
$96.69B17.8431.99%5.22%4.62%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GRFS
Grifols SA
9.14
2.50
37.65%
BMY
Bristol-Myers Squibb
47.63
9.45
24.75%
GILD
Gilead Sciences
111.51
47.00
72.86%
GSK
GlaxoSmithKline
38.51
1.64
4.45%
PFE
Pfizer
25.32
-0.64
-2.47%
SNY
Sanofi
49.31
1.96
4.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 06, 2025